Literature DB >> 25668345

Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients.

Peter K Bonfils1, Mustafa Taskiran, Morten Damgaard, Jens P Goetze, Andrea K Floyd, Peter Funch-Jensen, Viggo B Kristiansen, Mikael Støckel, Pierre N Bouchelouche, Niels Gadsbøll.   

Abstract

OBJECTIVE: To examine 24-h blood pressure (24BP), systemic haemodynamics and the effect of sodium intake on 24BP in obese patients before and after gastric bypass surgery [laparoscopic Roux-en-Y gastric bypass (LRYGB)], and to determine whether weight loss from LRYGB might be related to an increase in plasma concentrations of atrial natriuretic peptide.
METHODS: Twelve hypertensive and 12 normotensive morbidly obese patients underwent LRYGB: 24BP, systemic haemodynamics and mid-regional pro-atrial natriuretic peptide (MRproANP) were assessed before, 6 weeks and 12 months after surgery. The effect of high versus low sodium intake on 24BP was evaluated before and 12 months after LRYGB.
RESULTS: Six weeks after LRYGB, the average weight loss was 20 kg, with a further 21 kg weight loss 1 year after surgery. In hypertensive patients, 24BP was significantly reduced at 6 weeks, but not 1 year after LRYGB. However, antihypertensive medications were successively reduced from baseline to 1 year after surgery. In normotensive patients, there was no change in 24BP 6 weeks after LRYGB, but a tendency towards a reduction 1 year after the operation. Plasma concentrations of MRproANP were subnormal prior to surgery in hypertensive patients and increased by 77% 1 year after the operation. In normotensive patients, preoperative concentrations were normal and increased only by 6%. High sodium intake induced plasma volume expansion, increased stroke volume and cardiac output, but no significant change in 24BP - neither before nor after LRYGB.
CONCLUSIONS: LRYGB resulted in a significant 24BP reduction and a substantial increase in MRproANP plasma concentrations in hypertensive, obese patients 6 weeks after surgery, suggesting a causal link between obesity-hypertension and altered release/degradation of cardiac natriuretic peptides.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25668345     DOI: 10.1097/HJH.0000000000000526

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

Review 1.  Recognition and Management of Resistant Hypertension.

Authors:  Branko Braam; Sandra J Taler; Mahboob Rahman; Jennifer A Fillaus; Barbara A Greco; John P Forman; Efrain Reisin; Debbie L Cohen; Mohammad G Saklayen; S Susan Hedayati
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-28       Impact factor: 8.237

2.  Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults.

Authors:  Amanda L Willig; Andrew O Westfall; E Turner Overton; Michael J Mugavero; Greer A Burkholder; David Kim; Eric Chamot; James L Raper; Heidi M Crane; Michael S Saag; James H Willig
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-23       Impact factor: 2.205

Review 3.  Changes in Antihypertensive Medication Following Bariatric Surgery.

Authors:  Gabriel S Tajeu; Emily Johnson; Mason Buccilla; Crystal A Gadegbeku; Shane Janick; Daniel Rubin; Rohit Soans; Vikram J Eddy; David B Sarwer
Journal:  Obes Surg       Date:  2022-01-26       Impact factor: 3.479

4.  Time Course of Blood Pressure Decrease After Bariatric Surgery in Normotensive and Hypertensive Patients.

Authors:  Devon N Hawkins; Byron J Faler; Yong U Choi; Balakrishna M Prasad
Journal:  Obes Surg       Date:  2018-07       Impact factor: 4.129

5.  Patient-Reported Adherence to Empiric Vitamin/Mineral Supplementation and Related Nutrient Deficiencies After Roux-en-Y Gastric Bypass.

Authors:  Haleigh James; Paul Lorentz; Maria L Collazo-Clavell
Journal:  Obes Surg       Date:  2016-11       Impact factor: 4.129

6.  Dissociation Between Long-term Weight Loss Intervention and Blood Pressure: an 18-month Randomized Controlled Trial.

Authors:  Yftach Gepner; Nir Goldstein; Ilan Shelef; Dan Schwarzfuchs; Hila Zelicha; Anat Yaskolka Meir; Gal Tsaban; Ehud Grossman
Journal:  J Gen Intern Med       Date:  2021-02-25       Impact factor: 6.473

7.  Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma.

Authors:  Nicolai J Wewer Albrechtsen; Daniel Hornburg; Reidar Albrechtsen; Berit Svendsen; Signe Toräng; Sara L Jepsen; Rune E Kuhre; Marie Hansen; Charlotte Janus; Andrea Floyd; Asger Lund; Tina Vilsbøll; Filip K Knop; Henrik Vestergaard; Carolyn F Deacon; Felix Meissner; Matthias Mann; Jens J Holst; Bolette Hartmann
Journal:  EBioMedicine       Date:  2016-03-31       Impact factor: 8.143

Review 8.  Hypertension as a Metabolic Disorder and the Novel Role of the Gut.

Authors:  Masami Tanaka; Hiroshi Itoh
Journal:  Curr Hypertens Rep       Date:  2019-06-24       Impact factor: 5.369

9.  Non-interventional weight changes affect systolic blood pressure in normotensive individuals.

Authors:  Gadi Shlomai; Tal Ovdat; Robert Klempfner; Avshalom Leibowitz; Ehud Grossman
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-03-06       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.